Pacific Bio (PACB) Misses Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Pacific Biosciences of California (PACB) PT Raised to $32 at Cowen
November 3, 2021 6:30 AM EDTCowen analyst Dan Brennan raised the price target on Pacific Biosciences of California (NASDAQ: PACB) to $32.00 (from $30.00) while maintaining a Market Perform rating.
The analyst commented, "PACB reported a good 3Q, with revenues +83% Y/Y, ~5% ahead of expectations, and service, consumables, & instrument revenues... More
